Overview

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting
Trial end date:
2021-12-23
Target enrollment:
Participant gender:
Summary
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Thalidomide